Cargando…

Metabolomic profiles discriminating anxiety from depression

OBJECTIVE: Depression has been associated with metabolomic alterations. Depressive and anxiety disorders are often comorbid diagnoses and are suggested to share etiology. We investigated whether differential metabolomic alterations are present between anxiety and depressive disorders and which clini...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kluiver, Hilde, Jansen, Rick, Milaneschi, Yuri, Bot, Mariska, Giltay, Erik J., Schoevers, Robert, Penninx, Brenda W.J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361773/
https://www.ncbi.nlm.nih.gov/pubmed/33914921
http://dx.doi.org/10.1111/acps.13310
_version_ 1783738016199606272
author de Kluiver, Hilde
Jansen, Rick
Milaneschi, Yuri
Bot, Mariska
Giltay, Erik J.
Schoevers, Robert
Penninx, Brenda W.J.H.
author_facet de Kluiver, Hilde
Jansen, Rick
Milaneschi, Yuri
Bot, Mariska
Giltay, Erik J.
Schoevers, Robert
Penninx, Brenda W.J.H.
author_sort de Kluiver, Hilde
collection PubMed
description OBJECTIVE: Depression has been associated with metabolomic alterations. Depressive and anxiety disorders are often comorbid diagnoses and are suggested to share etiology. We investigated whether differential metabolomic alterations are present between anxiety and depressive disorders and which clinical characteristics of these disorders are related to metabolomic alterations. METHODS: Data were from the Netherlands Study of Depression and Anxiety (NESDA), including individuals with current comorbid anxiety and depressive disorders (N = 531), only a current depression (N = 304), only a current anxiety disorder (N = 548), remitted depressive and/or anxiety disorders (N = 897), and healthy controls (N = 634). Forty metabolites from a proton nuclear magnetic resonance lipid‐based metabolomics panel were analyzed. First, we examined differences in metabolites between disorder groups and healthy controls. Next, we assessed whether depression or anxiety clinical characteristics (severity and symptom duration) were associated with metabolites. RESULTS: As compared to healthy controls, seven metabolomic alterations were found in the group with only depression, reflecting an inflammatory (glycoprotein acetyls; Cohen's d = 0.12, p = 0.002) and atherogenic‐lipoprotein‐related (e.g., apolipoprotein B: Cohen's d = 0.08, p = 0.03, and VLDL cholesterol: Cohen's d = 0.08, p = 0.04) profile. The comorbid group showed an attenuated but similar pattern of deviations. No metabolomic alterations were found in the group with only anxiety disorders. The majority of metabolites associated with depression diagnosis were also associated with depression severity; no associations were found with anxiety severity or disease duration. CONCLUSION: While substantial clinical overlap exists between depressive and anxiety disorders, this study suggests that altered inflammatory and atherogenic‐lipoprotein‐related metabolomic profiles are uniquely associated with depression rather than anxiety disorders.
format Online
Article
Text
id pubmed-8361773
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83617732021-08-17 Metabolomic profiles discriminating anxiety from depression de Kluiver, Hilde Jansen, Rick Milaneschi, Yuri Bot, Mariska Giltay, Erik J. Schoevers, Robert Penninx, Brenda W.J.H. Acta Psychiatr Scand Original Articles OBJECTIVE: Depression has been associated with metabolomic alterations. Depressive and anxiety disorders are often comorbid diagnoses and are suggested to share etiology. We investigated whether differential metabolomic alterations are present between anxiety and depressive disorders and which clinical characteristics of these disorders are related to metabolomic alterations. METHODS: Data were from the Netherlands Study of Depression and Anxiety (NESDA), including individuals with current comorbid anxiety and depressive disorders (N = 531), only a current depression (N = 304), only a current anxiety disorder (N = 548), remitted depressive and/or anxiety disorders (N = 897), and healthy controls (N = 634). Forty metabolites from a proton nuclear magnetic resonance lipid‐based metabolomics panel were analyzed. First, we examined differences in metabolites between disorder groups and healthy controls. Next, we assessed whether depression or anxiety clinical characteristics (severity and symptom duration) were associated with metabolites. RESULTS: As compared to healthy controls, seven metabolomic alterations were found in the group with only depression, reflecting an inflammatory (glycoprotein acetyls; Cohen's d = 0.12, p = 0.002) and atherogenic‐lipoprotein‐related (e.g., apolipoprotein B: Cohen's d = 0.08, p = 0.03, and VLDL cholesterol: Cohen's d = 0.08, p = 0.04) profile. The comorbid group showed an attenuated but similar pattern of deviations. No metabolomic alterations were found in the group with only anxiety disorders. The majority of metabolites associated with depression diagnosis were also associated with depression severity; no associations were found with anxiety severity or disease duration. CONCLUSION: While substantial clinical overlap exists between depressive and anxiety disorders, this study suggests that altered inflammatory and atherogenic‐lipoprotein‐related metabolomic profiles are uniquely associated with depression rather than anxiety disorders. John Wiley and Sons Inc. 2021-05-25 2021-08 /pmc/articles/PMC8361773/ /pubmed/33914921 http://dx.doi.org/10.1111/acps.13310 Text en © 2021 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
de Kluiver, Hilde
Jansen, Rick
Milaneschi, Yuri
Bot, Mariska
Giltay, Erik J.
Schoevers, Robert
Penninx, Brenda W.J.H.
Metabolomic profiles discriminating anxiety from depression
title Metabolomic profiles discriminating anxiety from depression
title_full Metabolomic profiles discriminating anxiety from depression
title_fullStr Metabolomic profiles discriminating anxiety from depression
title_full_unstemmed Metabolomic profiles discriminating anxiety from depression
title_short Metabolomic profiles discriminating anxiety from depression
title_sort metabolomic profiles discriminating anxiety from depression
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361773/
https://www.ncbi.nlm.nih.gov/pubmed/33914921
http://dx.doi.org/10.1111/acps.13310
work_keys_str_mv AT dekluiverhilde metabolomicprofilesdiscriminatinganxietyfromdepression
AT jansenrick metabolomicprofilesdiscriminatinganxietyfromdepression
AT milaneschiyuri metabolomicprofilesdiscriminatinganxietyfromdepression
AT botmariska metabolomicprofilesdiscriminatinganxietyfromdepression
AT giltayerikj metabolomicprofilesdiscriminatinganxietyfromdepression
AT schoeversrobert metabolomicprofilesdiscriminatinganxietyfromdepression
AT penninxbrendawjh metabolomicprofilesdiscriminatinganxietyfromdepression